Press Releases Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
469.34 ^USD	-1.84%		+2.77%	+3.52%

03-11	Vertex Pharmaceuticals Incorporated Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11:30 AM
03-10	US Equity Markets Mixed Amid Volatility, Crude Oil Price Rebound	MT

Press Releases

03-13	AM Best Affirms Credit Ratings of Torreyana Insurance Company, Inc	AQ
03-09	Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy	BU
03-05	Vertex to Participate in Upcoming March Investor Conferences	BU
03-05	Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures	BU
02-17	Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3	BU
02-12	Vertex Pharmaceuticals Incorporated : Q4 2025 Presentation (6759ed5a 3de5 4ea9 81b2 ba99abfb333f)	PU
02-12	Vertex Reports Fourth Quarter and Full Year 2025 Financial Results	BU
01-26	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets	AQ
01-20	Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th	BU
01-12	Vertex Pharmaceuticals Incorporated : VRTX JPM 2026 Presentation vFINAL	PU
01-11	Vertex Pharmaceuticals Incorporated : Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings	PU
01-11	Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings	BU
12-29	Vertex Presents New CASGEVY® Data In Patients 5-11 Years And Announces Plan For Global Regulatory Submissions	AQ
12-22	Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12	BU
12-09	Pre-Grant Opposition Not Permitted After Signing Of Grant: Delhi High Court Affirms	AQ
12-06	Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions	BU
11-19	Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3	BU
11-09	Vertex Pharmaceuticals Incorporated : VRTX ASN Event Presentation 2025 Final	PU
11-08	Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week	BU
11-03	Vertex Pharmaceuticals Incorporated : Q3 2025 Earnings Presentation (7bd09616 955e 41a4 a1f2 cc1463a34521)	PU
11-03	Vertex Pharmaceuticals Incorporated : Reports Third Quarter 2025 Financial Results ( reports third quarter 2025 financial results)	PU
11-03	Vertex Reports Third Quarter 2025 Financial Results	BU
27/10/25	Vertex to Participate in the UBS Global Healthcare Conference on November 11	BU
24/10/25	Vertex Presents New Data across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK at the North American Cystic Fibrosis Conference	AQ
23/10/25	Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference	BU